SMT’s Supraflex stent clinically at par with Abbott’s Xience , with numerically better outcome:…
Patients who got Supraflex stent had target lesion failure occur among 6.9 per cent at 720 days vs 7.9 per cent of Xience…
Recover your password.
A password will be e-mailed to you.
- Advertisement -
Recover your password.
A password will be e-mailed to you.